EGRX - SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Eagle Pharmaceuticals Inc. - EGRX | Benzinga
NEW YORK, Dec. 22, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Eagle Pharmaceuticals, Inc. ("Eagle" or the "Company") (NASDAQ:EGRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
The investigation concerns whether Eagle and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On November 9, 2023, before the market opened, Eagle Pharmaceuticals announced that it would not release its third quarter 2023 results that day (as had been expected) because the Company "requires more time to review potential adjustments relating to the reporting of sales of PEMFEXY® prior to filing its Form 10-Q." The Company also disclosed it "expects to revise its previously disclosed 2023 full year guidance downward."
On this news, the Company's stock price fell $4.16 per share, or 30.4%, ...